FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571119330> ?p ?o ?g. }

• W2571119330 abstract "Abstract The use of reduced intensity conditioning has resulted in a significantly lower incidence of severe acute GVHD (aGVHD) compared with myeloablative conditioning. It is not known if reduced toxicity myeloablative conditioning has a similar impact. To answer this question, we evaluated the incidence of acute and chronic GVHD in a homogeneous group of AML/MDS patients treated with Fludarabine (Flu) and IV Busulfan (IVBu) between April 2001 and August 2005 at MD Anderson Cancer Center. METHODS: Retrospective analysis of all 195 consecutive AML/MDS patients (pts) who received conditioning with IVBu (130 mg/m2 for 4 days) and Flu (40 mg/m2 for 4 days) and allogeneic stem cell transplantation (ASCT). The cumulative incidence of GVHD was estimated considering disease progression or death in the absence of GVHD as competing risks. Cox’s proportional hazards regression analysis was used to compare the rates of GVHD. RESULTS: Median age at the time of transplantation was 46 years (12–65) with 4 pts being younger than 18 years. 45% of pts (n=93) were females and 47% (n=92) were in complete remission at the time of transplant. 55% (n=107) received a graft from a matched related donor (MRD), 38% (n=74) from a matched unrelated donor (MUD), and 7% (n=14) from a 1 Ag mismatched related or unrelated donor. Stem cell source was peripheral blood in 85% of recipients of a MRD graft and bone marrow in 88% of recipients of a MUD graft. The median number of CD34+ cells infused was 4.6 x 106/Kg (range 1.1–8.9) and 3.8 x106/Kg (range 0.2–13) in the two groups respectively. GVHD prophylaxis consisted of tacrolimus and mini-methotrexate. In addition, 29/74 recipients of a MUD graft received varying doses of pentostatin on a phase I/II clinical trial. Evaluation of GVHD was limited to pts who received a graft from a MRD or MUD and engrafted (n=179/181). With a median follow-up among survivors of 48 months (range 16–80), 100 day actuarial survival was similar in recipients of a MRD (96%) and MUD (93%) graft (p=0.3). A total of 50 pts (28%) developed grade II-IV and 15 pts (8%) grade III-IV aGVHD within 100 days after ASCT. Donor type was the most significant predictor of the incidence of grade II-IV aGVHD with a cumulative incidence of 18% (95% CI: 12–27) in recipients of a MRD graft and 38% (95% CI: 29–51) in recipients of a MUD graft (HR=0.4, p=0.001). Similarly the rate of grade III-IV aGVHD was significantly lower in recipients of a MRD graft (4% vs. 15%, HR=0.2, p=0.007). In contrast, donor type did not impact the incidence of chronic GVHD with a comparable cumulative incidence by 2 years in recipients of a MRD (53%, 95% CI: 44–63) and MUD graft (45%, 95% CI: 35–58), (HR=0.9, p=0.8). Similar results were observed when the comparison was restricted to de novo chronic GVHD (n=32). Use of peripheral blood stem cells was the only significant factor associated with a higher rate of chronic GVHD in recipients of a MRD graft (56% vs. 35%; HR=2.5, p=0.03). Female gender was associated with a significantly lower rate of chronic GVHD in recipients of a MUD graft (HR=0.4, p=0.006). There was no significant impact for age, percent donor chimerism at the time of engraftment, diagnosis (AML versus MDS), or donor/recipient CMV serostatus on the rate of grade II-IV aGVHD or chronic GVHD. CONCLUSION: The incidence of grade II-IV aGVHD is low following IVBuFlu conditioning and ASCT in AML/MDS patients. In this setting, donor type affects the incidence of acute but not chronic GVHD. Figure Figure" @default.
• W2571119330 created "2017-01-13" @default.
• W2571119330 creator A5004417292 @default.
• W2571119330 creator A5012412425 @default.
• W2571119330 creator A5016928938 @default.
• W2571119330 creator A5034104852 @default.
• W2571119330 creator A5034264716 @default.
• W2571119330 creator A5048913229 @default.
• W2571119330 creator A5057445061 @default.
• W2571119330 creator A5057832944 @default.
• W2571119330 creator A5066894053 @default.
• W2571119330 creator A5069460930 @default.
• W2571119330 creator A5070096873 @default.
• W2571119330 creator A5078965515 @default.
• W2571119330 date "2008-11-16" @default.
• W2571119330 modified "2023-09-30" @default.
• W2571119330 title "Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS." @default.
• W2571119330 doi "https://doi.org/10.1182/blood.v112.11.2227.2227" @default.
• W2571119330 hasPublicationYear "2008" @default.
• W2571119330 type Work @default.
• W2571119330 sameAs 2571119330 @default.
• W2571119330 citedByCount "0" @default.
• W2571119330 crossrefType "journal-article" @default.
• W2571119330 hasAuthorship W2571119330A5004417292 @default.
• W2571119330 hasAuthorship W2571119330A5012412425 @default.
• W2571119330 hasAuthorship W2571119330A5016928938 @default.
• W2571119330 hasAuthorship W2571119330A5034104852 @default.
• W2571119330 hasAuthorship W2571119330A5034264716 @default.
• W2571119330 hasAuthorship W2571119330A5048913229 @default.
• W2571119330 hasAuthorship W2571119330A5057445061 @default.
• W2571119330 hasAuthorship W2571119330A5057832944 @default.
• W2571119330 hasAuthorship W2571119330A5066894053 @default.
• W2571119330 hasAuthorship W2571119330A5069460930 @default.
• W2571119330 hasAuthorship W2571119330A5070096873 @default.
• W2571119330 hasAuthorship W2571119330A5078965515 @default.
• W2571119330 hasConcept C120665830 @default.
• W2571119330 hasConcept C121332964 @default.
• W2571119330 hasConcept C126322002 @default.
• W2571119330 hasConcept C141071460 @default.
• W2571119330 hasConcept C2776694085 @default.
• W2571119330 hasConcept C2776755627 @default.
• W2571119330 hasConcept C2777408962 @default.
• W2571119330 hasConcept C2778880498 @default.
• W2571119330 hasConcept C2779263901 @default.
• W2571119330 hasConcept C2779972918 @default.
• W2571119330 hasConcept C2780611847 @default.
• W2571119330 hasConcept C2911091166 @default.
• W2571119330 hasConcept C50382708 @default.
• W2571119330 hasConcept C61511704 @default.
• W2571119330 hasConcept C71924100 @default.
• W2571119330 hasConcept C88879693 @default.
• W2571119330 hasConcept C90924648 @default.
• W2571119330 hasConceptScore W2571119330C120665830 @default.
• W2571119330 hasConceptScore W2571119330C121332964 @default.
• W2571119330 hasConceptScore W2571119330C126322002 @default.
• W2571119330 hasConceptScore W2571119330C141071460 @default.
• W2571119330 hasConceptScore W2571119330C2776694085 @default.
• W2571119330 hasConceptScore W2571119330C2776755627 @default.
• W2571119330 hasConceptScore W2571119330C2777408962 @default.
• W2571119330 hasConceptScore W2571119330C2778880498 @default.
• W2571119330 hasConceptScore W2571119330C2779263901 @default.
• W2571119330 hasConceptScore W2571119330C2779972918 @default.
• W2571119330 hasConceptScore W2571119330C2780611847 @default.
• W2571119330 hasConceptScore W2571119330C2911091166 @default.
• W2571119330 hasConceptScore W2571119330C50382708 @default.
• W2571119330 hasConceptScore W2571119330C61511704 @default.
• W2571119330 hasConceptScore W2571119330C71924100 @default.
• W2571119330 hasConceptScore W2571119330C88879693 @default.
• W2571119330 hasConceptScore W2571119330C90924648 @default.
• W2571119330 hasLocation W25711193301 @default.
• W2571119330 hasOpenAccess W2571119330 @default.
• W2571119330 hasPrimaryLocation W25711193301 @default.
• W2571119330 hasRelatedWork W1195328187 @default.
• W2571119330 hasRelatedWork W1531313823 @default.
• W2571119330 hasRelatedWork W2256757852 @default.
• W2571119330 hasRelatedWork W2559543870 @default.
• W2571119330 hasRelatedWork W2560625365 @default.
• W2571119330 hasRelatedWork W2576729495 @default.
• W2571119330 hasRelatedWork W2586953154 @default.
• W2571119330 hasRelatedWork W2587485167 @default.
• W2571119330 hasRelatedWork W2588414062 @default.
• W2571119330 hasRelatedWork W2590830408 @default.
• W2571119330 hasRelatedWork W2593267567 @default.
• W2571119330 hasRelatedWork W2737527142 @default.
• W2571119330 hasRelatedWork W2913874211 @default.
• W2571119330 hasRelatedWork W2977246616 @default.
• W2571119330 hasRelatedWork W2980058028 @default.
• W2571119330 hasRelatedWork W2980918225 @default.
• W2571119330 hasRelatedWork W3001577031 @default.
• W2571119330 hasRelatedWork W3001837861 @default.
• W2571119330 hasRelatedWork W3138767028 @default.
• W2571119330 hasRelatedWork W32910850 @default.
• W2571119330 isParatext "false" @default.
• W2571119330 isRetracted "false" @default.
• W2571119330 magId "2571119330" @default.
• W2571119330 workType "article" @default.